ReviewCancer medicine2020
Intratumor heterogeneity: A new perspective on colorectal cancer research.
Review in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays.Annals of laboratory medicine · 2024Guideline
- Intratumor Heterogeneity as a Prognostic Factor in Solid Tumors: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Establishment, biobanking, and multi-omics characterization of 41 patient-derived colorectal cancer organoids: MYC/PRC classification.Translational oncology · 2026Article
- Whole Tumor Heterogeneity Topography (WTHT)-A New Approach for Assessment of Intratumor Mutational Heterogeneity in Colorectal Adenomas.International journal of molecular sciences · 2026Article
- The Oncogenic LncRNA-PVT1 in colorectal cancer: mechanisms of ceRNA-mediated progression and clinical implications.Medical oncology (Northwood, London, England) · 2026Review
- Article
- Opportunities and challenges of immuno-oncology: A bibliometric analysis from 2014 to 2023.Human vaccines & immunotherapeutics · 2025Review
- A plasma metabolite-based test to detect minimal residual disease in post-surgery patients with colorectal cancer.iScience · 2025Article
- Exploring the Role of Genetic and Environmental Features in Colorectal Cancer Development: An Agent-Based Approach.Entropy (Basel, Switzerland) · 2024Article
- From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Dissecting the Mechanisms of Intestinal Immune Homeostasis by Analyzing T-Cell Immune Response in Crohn's Disease and Colorectal Cancer.Current gene therapy · 2024Article
- Editorial: Clinical risk assessment and intervention of gastrointestinal tumors driven by big-data.Frontiers in medicine · 2024Article
- Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma.Cancers · 2023Article
- Disruptions in cell fate decisions and transformed enteroendocrine cells drive intestinal tumorigenesis in Drosophila.Cell reports · 2023Article
- Using picoliter droplet deposition to track clonal competition in adherent and organoid cancer cell cultures.Scientific reports · 2023Article
- Using Machine Learning Methods to Study Colorectal Cancer Tumor Micro-Environment and Its Biomarkers.International journal of molecular sciences · 2023Article
- Exploring the Role of Circulating Cell-Free RNA in the Development of Colorectal Cancer.International journal of molecular sciences · 2023Review
- Article
- A perfused multi-well bioreactor platform to assess tumor organoid response to a chemotherapeutic gradient.Frontiers in bioengineering and biotechnology · 2023Article
- Angiogenesis regulators S100A4, SPARC and SPP1 correlate with macrophage infiltration and are prognostic biomarkers in colon and rectal cancers.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancers generally consist of multiple subclones. These subclones have their own unique characteristics, resulting in intratumor heterogeneity (ITH). As the discussion of ITH has advanced, a model describing the relationship of ITH to the tumor has gradually emerged. ITH can be divided into two types of intraprimary tumor heterogeneity and intraindividual tumor heterogeneity, the former for further understanding of tumor composition, and the latter for providing more information about evolutionary patterns. With the rapid development of new methods, such as next-generation, polyguanine region sequencing, and Image detection, researchers may unravel the secrets underlying ITH. The higher the ITH of the tumor, the richer the interaction between the subclones maybe, or the greater the chance of the tumor getting more powerful subclones may be, thus increasing the malignant potential of the tumor. Existing evidence suggests that ITH may increase the ability of tumors to resist treatment and can be used as an independent influence on the prognosis of colorectal cancer. We reviewed 80 recent studies to give researchers a new perspective on colorectal cancer. There is still a limited amount of research in this area. Further study of the relationship between ITH and clinical endpoints may lead to the development of new treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.